CN115227739A - Chinese medicinal oral preparation for treating rheumatic arthralgia - Google Patents
Chinese medicinal oral preparation for treating rheumatic arthralgia Download PDFInfo
- Publication number
- CN115227739A CN115227739A CN202210987748.XA CN202210987748A CN115227739A CN 115227739 A CN115227739 A CN 115227739A CN 202210987748 A CN202210987748 A CN 202210987748A CN 115227739 A CN115227739 A CN 115227739A
- Authority
- CN
- China
- Prior art keywords
- herba
- group
- chinese medicinal
- oral preparation
- capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/237—Notopterygium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/254—Acanthopanax or Eleutherococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/56—Loganiaceae (Logania family), e.g. trumpetflower or pinkroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a traditional Chinese medicine oral preparation for treating rheumatic arthralgia, which is prepared by processing ten kinds of Chinese medicinal herbs including Chinese taxillus twig, nux vomica, lycopodium clavatum, garden balsam stem, hiraute shiny bugleweed herb, cassia twig, notopterygium root, frankincense, cortex acanthopanacis and erythrina bark; the composition has effects of dispelling pathogenic wind, removing dampness, relieving swelling and pain; the traditional Chinese medicine oral preparation is safe, has no toxic or side effect, and has obvious curative effects on the rheumatic arthralgia, the joint pain and the rheumatic edema. The clinical pharmacodynamics test has obvious effect, high bioavailability and no toxic or side effect.
Description
Technical Field
The invention relates to a traditional Chinese medicine oral preparation for treating rheumatic arthralgia, belonging to the technical field of pharmacy.
Technical Field
Rheumatic arthritis and rheumatoid arthritis are autoimmune diseases of human beings, and the causes of the diseases are not clear at present; the main symptoms are persistent joint swelling and pain, the pain is aggravated in rainy days, and serious people can cause disability and labor loss, thereby seriously harming the physical health of human beings. At present, many traditional Chinese medicines for treating the rheumatic arthritis are orally taken, but most of the traditional Chinese medicines have unsatisfactory curative effect. Searching in the prior art: 1. chinese patent gazette 3-29.2022 discloses a patent application entitled "a wind-expelling and cold-dispelling medicine for treating muscle and bone pain and its preparation method" publication No. CN114246899A, which comprises the following raw material medicines: 2 parts of monkshood, 10 parts of poria with hostwood, 10 parts of uncaria, 20 parts of cinnamomum japonicum, 20 parts of Chinese angelica, 3 parts of radix rehmanniae, 20 parts of radix angelicae pubescentis, 50 parts of loranthus parasiticus, 20 parts of gentiana macrophylla, 20 parts of teasel root, 2 parts of ligusticum wallichii, 20 parts of peach kernel, 20 parts of safflower, 20 parts of frankincense, 20 parts of berba aristolochiae mollissimae, 20 parts of myrrh and 10 parts of bungarus parvus; the applicant conducts experimental research on the prior art and finds that the effect of the traditional Chinese medicine composition for treating rheumatoid arthritis and rheumatoid arthritis is not ideal and the composition is complex. Therefore, the research and development of the traditional Chinese medicine oral preparation for treating the rheumatic arthralgia, the arthralgia and the rheumatic edema has simple formula and obvious curative effect and can generate great social and economic benefits. The composition has effects of dispelling pathogenic wind, removing dampness, relieving swelling and pain; the traditional Chinese medicine oral preparation is mainly used for treating rheumatism pain, joint pain, rheumatism edema and other symptoms, and has the advantages of obvious curative effect, safety and no toxic or side effect. The traditional Chinese medicine composition has the advantages of obvious clinical pharmacodynamic test effect, high bioavailability and no toxic or side effect, and can be prepared into oral tablets, capsules and granules according to the conventional process.
Disclosure of Invention
The invention aims to overcome the defects of the prior art in the field, and provides a traditional Chinese medicine oral preparation for treating rheumatic arthralgia, which is scientific in prescription, remarkable in curative effect and free of toxic and side effects on a human body through a large number of pharmacodynamic experiments and a large number of clinical pharmacodynamic researches.
The invention also aims to provide a preparation method of the traditional Chinese medicine oral preparation.
In order to achieve the purpose, the invention adopts the technical scheme that:
the invention relates to a traditional Chinese medicine oral preparation for treating rheumatic arthralgia, which comprises the following components in percentage by weight:
the traditional Chinese medicine composition disclosed by the invention comprises the following preferable components in percentage by weight:
the preparation method of the traditional Chinese medicine oral preparation for treating rheumatic arthralgia comprises the following steps:
1. the preparation method of the tablet comprises the following steps:
pulverizing herba Taxilli, semen Strychni, herba Lycopodii, herba Speranskiae Tuberculatae, herba Lycopi, ramulus Cinnamomi, notopterygii rhizoma, olibanum, cortex Acanthopanacis and cortex Erythrinae into fine powder respectively, mixing well, granulating, drying, grading, and tabletting to obtain tablet.
2. The preparation method of the capsule comprises the following steps:
pulverizing herba Taxilli, semen Strychni, herba Lycopodii, herba Speranskiae Tuberculatae, herba Lycopi, ramulus Cinnamomi, notopterygii rhizoma, olibanum, cortex Acanthopanacis and cortex Erythrinae into fine powder respectively, mixing well, granulating, drying, grading, and making into capsule to obtain capsule.
3. The preparation method of the granules comprises the following steps:
pulverizing herba Taxilli, semen Strychni, herba Lycopodii, herba speranskiae tuberculatae, herba Lycopi, ramulus Cinnamomi, rhizoma Et radix Notopterygii, olibanum, cortex Acanthopancis, and cortex erythrinae into fine powder, adding appropriate amount of correctant, mixing, granulating, drying, grading, and packaging to obtain granule.
At present, a lot of traditional Chinese medicines for treating rheumatoid arthritis are orally taken, but most of the traditional Chinese medicines have unsatisfactory curative effect. Searching in the prior art: 1. chinese patent gazette 3-29.2022 discloses a patent application entitled "a wind-expelling and cold-dispelling medicine for treating muscle and bone pain and its preparation method" publication No. CN114246899A, which comprises the following raw material medicines: 2 parts of monkshood, 10 parts of poria with hostwood, 10 parts of uncaria, 20 parts of cinnamomum japonicum, 20 parts of Chinese angelica, 3 parts of radix rehmanniae, 20 parts of radix angelicae pubescentis, 50 parts of loranthus parasiticus, 20 parts of large-leaved gentian, 20 parts of teasel root, 2 parts of ligusticum wallichii, 20 parts of peach kernel, 20 parts of safflower, 20 parts of frankincense, 20 parts of mollissima, 20 parts of myrrh and 10 parts of bungarus fasciatus; the applicant conducts experimental research on the prior art, and finds that the effect of the traditional Chinese medicine composition for treating rheumatoid and rheumatic arthritis is not ideal, and the formula is complex.
Aiming at the problems in the prior art, the inventor combines a large number of traditional Chinese medicine formula theories and a large number of pharmacodynamics experiments to invent a traditional Chinese medicine oral preparation with obvious curative effect on treating rheumatic arthralgia, joint pain and rheumatic edema. The composition has effects of dispelling pathogenic wind, removing dampness, relieving swelling and pain; the traditional Chinese medicine oral preparation is mainly used for treating symptoms such as rheumatic arthralgia, joint pain, rheumatic edema and the like, has obvious clinical pharmacodynamic test effect and high bioavailability, and does not have any toxic or side effect. The traditional Chinese medicine composition is prepared into oral tablets, capsules and granules according to the conventional process.
Main pharmacodynamic tests:
1. pharmacodynamic tests of the invention: compared with the prior art, the traditional Chinese medicine oral preparation has obvious pharmacodynamic test effect.
The formula raw material medicine proportion of the invention is the best raw material medicine proportion obtained by strict pharmacological screening test.
Through patent retrieval, the prior art documents are as follows:
comparison document 1: chinese patent publication No. 3/29/2022 discloses a patent application entitled "a wind-expelling and cold-dispelling medicine for treating muscle and bone pain and its preparation method" publication No. CN 114246899A.
The main pharmacodynamic tests prove that:
compared with the medicine prepared by the weight ratio and the process of each medicinal material in the embodiment 2 of the specification of the comparison document 1, the capsule prepared by the weight ratio of each raw medicinal material in the traditional Chinese medicine oral preparation group has the advantage that the pharmacodynamics test result of the capsule is obviously higher than that of the medicine prepared by the method in the embodiment 2 of the comparison document 1. The main pharmacodynamic tests are as follows:
preparation of experimental drugs:
1. the capsule group of the invention: capsules prepared according to the description of the invention, example 1.
2. Group a the drug prepared according to the method of example 2 of the embodiment of the patent application publication No. CN114246899A of the comparison document 1.
(II) pharmacodynamic experiment process:
purpose of the experiment: through pharmacological experimental study on the effects of the capsule group and the group a, such as anti-inflammation, analgesia, microcirculation improvement, soft tissue injury protection and the like, the capsule group and the group a are compared, and the strength of the pharmacological effect is observed.
The test method comprises the following steps: the capsule group and group a of the invention have the influence on the swelling of the feet of the mouse caused by carrageenan; effect on mouse skin capillary permeability; influence on writhing response of mice caused by acetic acid; effects on mouse auricle microcirculation; effect on acute soft tissue injury in rats.
1. Effect on carrageenan-induced swelling of mouse feet
Experimental materials
1. Animals: the Kunming mouse has both male and female bodies and has the weight of 18-22 g.
2. Medicine preparation: the invention capsule group and group a; the medicine fine powder is mixed with distilled water before experiment and administrated through gastric lavage.
Experimental method
30 Kunming mice with half male and half female, the weight of 18-22 g are randomly divided into 3 groups, and each group comprises 10 mice. The control group was perfused with normal saline of the same volume; the capsule group and the group a are respectively administrated by gavage with 0.4g crude drugs/kg. The administration is continued for 5 days, 1 time daily, 1h after the last administration, and 0.03ml of 1% carrageenan solution is injected subcutaneously into the plantar surface of the left hind limb and foot of the mouse. The mice were sacrificed after 4h cervical dislocation after drug injection, and the left and right hind paws were cut off from the knee joint and weighed, respectively, and the difference between the weights of the two paw was taken as the swelling degree. The experimental results are as follows: see Table 1
TABLE 1 Effect on carrageenan-induced swelling of mouse feet
P < 0.01 compared to control group; * P is less than 0.05; compared with the capsule composition of the invention, the delta P is less than 0.05.
The results show that: the capsule group and the group a can obviously inhibit the mouse foot swelling caused by carrageenan, and the capsule group has very significant difference (P is less than 0.01) compared with a control group; the group a has significant difference (P < 0.05) compared with the control group; compared with the group a, the capsule group of the invention has significant difference (P is less than 0.05). Therefore, the capsule group of the invention has stronger anti-inflammatory effect than the group a.
2. Effect on mouse skin capillary Permeability
Experimental Material
1. Animals: the Kunming mouse has both male and female bodies and the weight is 18 to 22g.
2. Medicine preparation: the invention capsule group and group a; the fine powder of the medicine is mixed with distilled water evenly before the experiment, and the medicine is administrated by gastric lavage.
Experimental methods
30 Kunming mice with half male and half female, the weight of 18-22 g are randomly divided into 3 groups, and each group comprises 10 mice. The control group was perfused with normal saline of the same volume; the capsule group and the group a are respectively administrated by gavage with 0.4g crude drugs/kg. Continuously administering for 5d, after 1h of the last administration, intravenously injecting 0.5% Evans blue 0.2ml/10g per tail, immediately performing intraperitoneal injection of 0.8% acetic acid solution 0.1ml/10g to cause inflammation, killing the mice after 0.5h, flushing the abdominal cavity with 5ml of normal saline, collecting flushing fluid, centrifuging, taking supernatant, and performing colorimetric determination on the supernatant at a spectrophotometer wavelength of 61Onm to obtain an absorbance value. The experimental results are as follows: see Table 2
TABLE 2 Effect on mouse skin capillary Permeability
P < 0.01 compared to control group; * P is less than 0.05; compared with the capsule composition of the invention, the delta P is less than 0.05.
The results show that: the capsule group and the group a have obvious inhibiting effect on hyperfunction of the skin capillary permeability of the mice, and compared with a control group, the capsule group has extremely obvious difference (P is less than 0.01); the group a has significant difference (P < 0.05) compared with the control group; compared with the group a, the capsule group of the invention has significant difference (P is less than 0.05). Therefore, the capsule preparation group has stronger inhibiting effect on edema, inflammation and exudation than the group a.
3. Influence on writhing response of mice caused by acetic acid
Experimental Material
1. Animals: the Kunming mouse has both male and female bodies and the weight is 18 to 22g.
2. Medicine preparation: the invention capsule group and group a; the medicine fine powder is mixed with distilled water before experiment and administrated through gastric lavage.
Experimental methods
30 Kunming mice with half male and half female, the weight of 18-22 g are randomly divided into 3 groups, and each group comprises 10 mice. The control group was perfused with the same volume of normal saline; the capsule group and the group a are respectively administrated by gavage with 0.4g crude drugs/kg. The administration is continued for 5 days, and after 0.5h of the last administration, 0.6% acetic acid is injected into the abdominal cavity of each mouse, and the times of writhing of the mice within 20min are recorded. The experimental results are as follows: see Table 3
TABLE 3 Effect on acetic acid induced writhing response in mice
P < 0.01 compared to control group; * P is less than 0.05; compared with the capsule composition of the invention, the delta P is less than 0.05.
The results show that the capsule group and the group a have obvious inhibition effect on mouse writhing caused by acetic acid, and the capsule group has very significant difference (P is less than 0.01) compared with a control group; the a group is significantly different from the control group (P < 0.05); compared with the group a, the capsule group of the invention has significant difference (P is less than 0.05). Therefore, the pain relieving effect of the capsule group is stronger than that of the group a.
4. Effect on mouse auricle microcirculation
Experimental Material
1. Animals: the Kunming mouse has both male and female bodies and the weight is 18 to 22g.
2. Medicine preparation: the invention is capsule group and group a; the medicine fine powder is mixed with distilled water before experiment and administrated through gastric lavage.
Experimental methods
30 Kunming mice, each half of male and female, with the weight of 18-22 g, were randomly divided into 3 groups of 10 mice each. The control group was perfused with the same volume of normal saline; the capsule group and the group a are respectively administrated by gavage with 0.4g crude drugs/kg. The administration was continued for 5 days, 1 time daily. After 0.5h of the last administration, each group of mice was anesthetized with intraperitoneal injection of 20% urethane at 0.07ml/10g, the abdomen of the mice was placed on an optical microscope stage, the auricles of the mice were flattened, a small amount of liquid paraffin was dropped on the surface of the auricles, the brightness of a light source was adjusted, the influence of the drug on the microcirculation of the auricles of the mice was observed under transmitted light by a 6 × 10 microscope, and the velocity of the micro blood flow was measured. The experimental results are as follows: see Table 4
TABLE 4 Effect on mouse auricle microcirculation
P < 0.01 compared to control group; * P is less than 0.05; compared with the capsule of the invention, the delta P is less than 0.05.
The results show that: the capsule group and the group a can obviously increase the speed of the mouse auricle micro-blood flow and promote the blood circulation. Compared with a control group, the capsule group has extremely significant difference (P is less than 0.01); the a group is significantly different from the control group (P < 0.05); compared with the group a, the capsule group of the invention has significant difference (P is less than 0.05). Therefore, the capsule group of the invention has stronger microcirculation improving effect than the group a.
5. Effect on acute Soft tissue injury in rats
Experimental materials
1. Animals: wistar rats have both male and female bodies and weight of 180-220 g.
2. Medicine preparation: the invention is capsule group and group a; the fine powder of the medicine is mixed with distilled water evenly before the experiment, and the medicine is administrated by gastric lavage.
Experimental methods
The local area of the outer side of the right hind limb of the rat is about 2cm multiplied by 2cm, the rat is fixed on a wood board the next day after depilation, a PVC hollow pipe with the inner diameter of 1.5cm and the length of 100cm is vertically arranged on the soft tissue of the outer side of the right hind limb of the rat, and then a blunt iron pestle weighing 80g freely falls from top to bottom to impact the soft tissue of the outer side of the right hind limb of the rat for 3 times continuously, so that the local area of about 4cm is caused 2 The model of unopened soft tissue injury with obvious subcutaneous hemorrhage and swelling was operated with the injured parts of each rat as close as possible. 30 Wistar rats, each half of male and female, weighing 180-220 g, which were prepared into tissue injury models by the above method were randomly divided into 3 groups of 10 rats each. The control group was perfused with the same volume of normal saline; the capsule group and the group a are respectively administrated by intragastric administration, wherein the weight of the capsule group and the group a is 0.2g of crude drug/kg. The administration is continued for 5 days, 1 time per day, and after 1 hour of the last administration, the difference between the circumferences of the injured part of the right limb and the same part of the left limb is measured by a flexible ruler to be used as a swelling degree value. The experimental results are as follows: see Table 5
TABLE 5 Effect on acute Soft tissue injury in rats
P < 0.01 compared to control group; * P is less than 0.05; compared with the capsule composition of the invention, the delta P is less than 0.05.
The results show that: the capsule group and the group a have obvious effect of relieving acute soft tissue swelling of rats caused by striking, and compared with a control group, the capsule group has very significant difference (P is less than 0.01); the a group is significantly different from the control group (P < 0.05); compared with the group a, the capsule group of the invention has significant difference (P is less than 0.05). Thus, the capsule group of the present invention provides greater protection against acute soft tissue injury than group a.
The experimental results are as follows: the capsule group and the group a can obviously inhibit the swelling of the feet of the mouse caused by the carrageenan; the composition has a remarkable inhibitory effect on hyperfunction of the skin capillary permeability of mice; the inhibitor has obvious inhibition effect on the writhing of mice caused by acetic acid; the speed of the mouse auricle micro blood flow can be obviously increased, and the blood circulation is promoted; has obvious effect of relieving acute soft tissue swelling of rats caused by striking.
And (4) conclusion: compared with the group a, the capsule group has stronger effects of resisting inflammation, easing pain, improving microcirculation, protecting soft tissue injury and the like, so the capsule group has better treatment effect of dispelling wind, removing dampness, reducing swelling and relieving pain than the group a in clinical use.
The specific implementation mode of the invention is as follows:
example 1
Prescription:
the preparation method comprises the following steps:
pulverizing herba Taxilli, semen Strychni, herba Lycopodii, herba speranskiae tuberculatae, herba Lycopi, ramulus Cinnamomi, rhizoma Et radix Notopterygii, olibanum, cortex Acanthopancis, and cortex erythrinae into fine powder, mixing, granulating, drying, grading, and making into capsule.
Example 2
Prescription:
the preparation method comprises the following steps:
pulverizing herba Taxilli, semen Strychni, herba Lycopodii, herba speranskiae tuberculatae, herba Lycopi, ramulus Cinnamomi, rhizoma Et radix Notopterygii, olibanum, cortex Acanthopancis, and cortex erythrinae into fine powder, mixing, granulating, drying, grading, and tabletting to obtain tablet.
Example 3
Prescription:
the preparation method comprises the following steps:
pulverizing herba Taxilli, semen Strychni, herba Lycopodii, herba Speranskiae Tuberculatae, herba Lycopi, ramulus Cinnamomi, notopterygii rhizoma, olibanum, cortex Acanthopanacis and cortex Erythrinae into fine powder respectively, adding appropriate amount of correctant, mixing, granulating, drying, grading, and packaging to obtain granule.
Example 4
Prescription:
the preparation method comprises the following steps:
pulverizing herba Taxilli, semen Strychni, herba Lycopodii, herba speranskiae tuberculatae, herba Lycopi, ramulus Cinnamomi, rhizoma Et radix Notopterygii, olibanum, cortex Acanthopancis, and cortex erythrinae into fine powder, mixing, granulating, drying, grading, and making into capsule.
Example 5
Prescription:
the preparation method comprises the following steps:
pulverizing herba Taxilli, semen Strychni, herba Lycopodii, herba Speranskiae Tuberculatae, herba Lycopi, ramulus Cinnamomi, notopterygii rhizoma, olibanum, cortex Acanthopanacis and cortex Erythrinae into fine powder respectively, mixing well, granulating, drying, grading, and tabletting to obtain tablet.
Example 6
Prescription:
the preparation method comprises the following steps:
pulverizing herba Taxilli, semen Strychni, herba Lycopodii, herba speranskiae tuberculatae, herba Lycopi, ramulus Cinnamomi, rhizoma Et radix Notopterygii, olibanum, cortex Acanthopancis, and cortex erythrinae into fine powder, adding appropriate amount of correctant, mixing, granulating, drying, grading, and packaging to obtain granule.
Example 7
Prescription:
the preparation method comprises the following steps:
pulverizing herba Taxilli, semen Strychni, herba Lycopodii, herba speranskiae tuberculatae, herba Lycopi, ramulus Cinnamomi, rhizoma Et radix Notopterygii, olibanum, cortex Acanthopancis, and cortex erythrinae into fine powder, mixing, granulating, drying, grading, and making into capsule.
Example 8
Prescription:
the preparation method comprises the following steps:
pulverizing herba Taxilli, semen Strychni, herba Lycopodii, herba Speranskiae Tuberculatae, herba Lycopi, ramulus Cinnamomi, notopterygii rhizoma, olibanum, cortex Acanthopanacis and cortex Erythrinae into fine powder respectively, mixing well, granulating, drying, grading, and tabletting to obtain tablet.
Example 9
Prescription:
the preparation method comprises the following steps:
pulverizing herba Taxilli, semen Strychni, herba Lycopodii, herba speranskiae tuberculatae, herba Lycopi, ramulus Cinnamomi, rhizoma Et radix Notopterygii, olibanum, cortex Acanthopancis, and cortex erythrinae into fine powder, adding appropriate amount of correctant, mixing, granulating, drying, grading, and packaging to obtain granule.
Claims (7)
1. A traditional Chinese medicine oral preparation for treating rheumatic arthralgia is characterized in that the traditional Chinese medicine oral preparation comprises the following components in percentage by weight:
2. the oral Chinese medicinal preparation according to claim 1, wherein the formula of the oral Chinese medicinal preparation is preferably:
3. the oral Chinese medicinal preparation according to claim 1 or 2, wherein: the dosage form of the Chinese medicinal oral preparation is a pharmaceutically acceptable dosage form, and is selected from tablets, capsules or granules.
4. The method for preparing a Chinese medicinal oral preparation according to claim 1, 2 or 3, wherein:
pulverizing herba Taxilli, semen Strychni, herba Lycopodii, herba Speranskiae Tuberculatae, herba Lycopi, ramulus Cinnamomi, notopterygii rhizoma, olibanum, cortex Acanthopanacis and cortex Erythrinae into fine powder respectively, mixing well, granulating, drying, grading, and tabletting to obtain tablet.
5. The method for preparing a Chinese medicinal oral preparation according to claim 1, 2 or 3, wherein:
pulverizing herba Taxilli, semen Strychni, herba Lycopodii, herba Speranskiae Tuberculatae, herba Lycopi, ramulus Cinnamomi, notopterygii rhizoma, olibanum, cortex Acanthopanacis and cortex Erythrinae into fine powder respectively, mixing well, granulating, drying, grading, and making into capsule to obtain capsule.
6. The method for preparing a Chinese medicinal oral preparation according to claim 1, 2 or 3, wherein:
pulverizing herba Taxilli, semen Strychni, herba Lycopodii, herba speranskiae tuberculatae, herba Lycopi, ramulus Cinnamomi, rhizoma Et radix Notopterygii, olibanum, cortex Acanthopancis, and cortex erythrinae into fine powder, adding appropriate amount of correctant, mixing, granulating, drying, grading, and packaging to obtain granule.
7. The oral Chinese medicinal preparation according to claim 1, 2, 3, 4, 5 or 6, which is used for treating rheumatic arthralgia, joint pain, rheumatic edema and the like.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210987748.XA CN115227739B (en) | 2022-08-17 | 2022-08-17 | Chinese medicinal oral preparation for treating rheumatalgia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210987748.XA CN115227739B (en) | 2022-08-17 | 2022-08-17 | Chinese medicinal oral preparation for treating rheumatalgia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115227739A true CN115227739A (en) | 2022-10-25 |
| CN115227739B CN115227739B (en) | 2023-06-30 |
Family
ID=83679151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210987748.XA Active CN115227739B (en) | 2022-08-17 | 2022-08-17 | Chinese medicinal oral preparation for treating rheumatalgia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115227739B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105079110A (en) * | 2015-09-21 | 2015-11-25 | 王艳平 | Medicinal liquor for treating rheumatoid and preparation method of medicinal liquor |
| CN107050115A (en) * | 2017-03-09 | 2017-08-18 | 吉林修正药业新药开发有限公司 | The new application of Chinese patent drug neck waist health |
| CN107441192A (en) * | 2016-06-01 | 2017-12-08 | 陈丽 | A kind of Wash-out medicine for controlling rheumatoid |
| CN114246899A (en) * | 2021-11-30 | 2022-03-29 | 湖南省开元博物馆 | Wind-expelling and cold-dispelling medicine for treating muscle and bone pain and preparation method thereof |
-
2022
- 2022-08-17 CN CN202210987748.XA patent/CN115227739B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105079110A (en) * | 2015-09-21 | 2015-11-25 | 王艳平 | Medicinal liquor for treating rheumatoid and preparation method of medicinal liquor |
| CN107441192A (en) * | 2016-06-01 | 2017-12-08 | 陈丽 | A kind of Wash-out medicine for controlling rheumatoid |
| CN107050115A (en) * | 2017-03-09 | 2017-08-18 | 吉林修正药业新药开发有限公司 | The new application of Chinese patent drug neck waist health |
| CN114246899A (en) * | 2021-11-30 | 2022-03-29 | 湖南省开元博物馆 | Wind-expelling and cold-dispelling medicine for treating muscle and bone pain and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 岳敏，等: "风湿正痛丸治疗寒湿痹阻型类风湿关节炎临床疗效观察", 辽宁中医杂志 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115227739B (en) | 2023-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101032580B (en) | Medicine for treating rheumatic diseases | |
| CN102698014B (en) | Chinese medicinal composition for treating bone-related diseases and preparation method and application thereof | |
| CN104288228A (en) | Traditional Chinese medicine composite for treating pain in neck, shoulders, waist and legs | |
| CN103736017A (en) | Traditional Chinese medicine composition for treating intercostal neuralgia and preparation method of traditional Chinese medicine composition | |
| CN103251766A (en) | Chinese medicine composition, and clinical preparation and preparation method thereof | |
| CN115227739A (en) | Chinese medicinal oral preparation for treating rheumatic arthralgia | |
| CN105214010A (en) | A kind of Chinese medicine preparation for the treatment of chronic cholecystitis | |
| CN104922363A (en) | Traditional Chinese medicine composite for treating osteoproliferation | |
| CN106668782A (en) | External traditional Chinese medicine preparation for treating knee osteoarthritis and preparation method thereof | |
| CN104958416A (en) | Chinese medicinal preparation for treating sciatica and preparation method thereof | |
| CN115252742B (en) | A Chinese medicinal oral preparation for treating traumatic injury and fracture | |
| CN104721631A (en) | Traditional Chinese medicine composition for promoting wound healing and preparation method of traditional Chinese medicine composition | |
| CN104940469A (en) | Traditional Chinese medicine preparation for treating burns and scalds through external application and preparation method of traditional Chinese medicine preparation | |
| CN103961490A (en) | Compound medicine for treating wind-cold-dampness arthralgia and preparation method thereof | |
| CN104721427A (en) | Traditional Chinese medicine preparation for treating rheumatic bone diseases | |
| CN103251765A (en) | Traditional Chinese medicine composition for treating lumbar intervertebral disc herniation and preparation method thereof | |
| CN109157635B (en) | Honeysuckle stem compound with anti-depression effect and preparation method and application thereof | |
| CN105641586A (en) | Fengtongning preparation and preparation method thereof | |
| CN107281444B (en) | Analgesic pharmaceutical composition and preparation method and application thereof | |
| CN1181835C (en) | Chinese medicine preparation for treating rheumatism and rheumatoid disease | |
| CN105497817A (en) | Chinese herbal preparation for treating turgescence caused by trauma of ankle joint and preparation method thereof | |
| CN1314431C (en) | Traditional Chinese medicine for treeting gonarthrosis | |
| CN105288086A (en) | Traditional Chinese medicine composition for treating cerebral thrombosis and preparing method thereof | |
| CN116270949A (en) | Traditional Chinese medicine composition for reducing hyperuricemia and preparation method thereof | |
| CN102526386A (en) | Obscured homalomenarhizome and earthworm joint swelling relieving fumigation preparation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |